Acute Cardiac Ischemia

Pharma company advances compound for diagnosis of acute cardiac ischemia

Published in Clinical Oncology Week, May 16th, 2005

Molecular Insight Pharmaceuticals, Inc., said it has raised $28 million in a series C financing to advance its lead compound, BMIPP, into phase 3 clinical trials for the diagnosis of acute cardiac ischemia and to accelerate the development of the company's pipeline of molecular imaging pharmaceuticals and radiotherapeutics.

New investors, including Siemens Venture Capital GmbH, Corp., Tudor Investment Corp., MedCap Management & Research LLC, and Emigrant Capital Corp. joined existing institutional and individual investors in the financing round. SG Cowen & Co. served as placement agent.

"BMIPP has great potential to be the first product to enable...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Clinical Oncology Week

Source: Clinical Oncology Week (2005-05-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry